Clinical Trial Update: RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating RO4929097 in combination with exemestane in pre- and postmenopausal patients with advanced or metastatic breast cancer has been termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Positive, HER2/Neu Negative | Phase 1 | Status: TERMINATED